A phase II trial of intraperitoneal cisplatin and etoposide as consolidation therapy in patients with stage II-IV epithelial ovarian cancer following negative surgical assessment

Gynecologic Oncology

Volumn 69, Issue 1, 1998, Pages 17-22

  Barakat, Richard R ^a   Almadrones, Lois ^a   Venkatraman, Ennapadam S ^a   Aghajanian, Carol ^a   Brown, Carol ^a   Shapiro, Fred ^a   Curtin, John P ^a   Spriggs, David ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; ETOPOSIDE;

ABDOMINAL PAIN; ADULT; AGED; ARTICLE; CANCER GRADING; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; FEMALE; FEVER; HUMAN; INTRAPERITONEAL DRUG ADMINISTRATION; LEUKOPENIA; NAUSEA; NEUTROPENIA; OVARY CANCER; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SECOND LOOK SURGERY; VOMITING;

EID: 0032054093     PISSN: 00908258     EISSN: None     Source Type: Journal    
DOI: 10.1006/gyno.1998.4973     Document Type: Article

References (20)

1. Ozols RF, Rubin SC, Thomas G: Epithelial ovarian cancer, in Hoskins WJ, Perez CA, Young RC (eds): Principles and Practice of Gynecologic Oncology, 2nd ed. Philadelphia, Lippincott, 1996, p 960, Table 32-15
2. Rubin SC, Hoskins WJ, Saigo PE: Prognostic factors for recurrence following negative second-look laparotomy in ovarian cancer patients treated with platinum-based chemotherapy. Gynecol Oncol 42:137-141, 1991
3. Markman M: Intraperitoneal antineoplastic agents for tumors principally confined to the peritoneal cavity. Cancer Treat Rev 13:219-242, 1986
4. Reichman B, Markman M, Hakes T: Intraperitoneal cisplatin and etoposide in the treatment of refractory/recurrent ovarian carcinoma. J Clin Oncol 7:1327-1332, 1989
5. Cain J, Saigo P, Pierce V: A review of second-look laparotomy for ovarian cancer. Gynecol Oncol 23:14, 1986
6. Abu-Rustum N, Barakat R, Siegel P: Second-look operation for epithelial ovarian cancer: laparoscopy or laparotomy? Obstet Gynecol 88:549-553, 1996
7. Kaplan E, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958
8. Mantel N: Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother 59:163-170, 1966
9. Cox D: Regression models and life tables. JR Stat Soc Sect B 34:187-202, 1972
10. Hakes T, Chalas E, Hoskins WJ: Randomized prospective trial of 5 versus 10 cycles of cyclophosphamide, doxorubicin and cisplatin in advanced ovarian carcinoma. Gynecol Oncol 45:284-289, 1992
11. Fuks Z, Rizel S, Biran S: Chemotherapeutic and surgical induction of pathological complete remission and whole abdominal irradiation for consolidation does not enhance the cure of stage III ovarian carcinoma. J Clin Oncol 6:509-516, 1988
12. Spencer TR, Marks RD, Fenn JO: Intraperitoneal p32 after negative second look laparotomy in ovarian carcinoma. Cancer 63:2434-2437, 1989
13. 32P is not effective consolidation therapy after a negative second-look laparotomy for epithelial carcinoma of the ovary. Gynecol Oncol 45:76, 1992
14. Dufour P, Bergerat JP, Liu KL, Bohbot A, Maloisel F, Duclos B, Herbrecht R, Faradji A, Jung JM, Oberling F: High dose melphalan and ABMT with or without radiotherapy as consolidation treatment for ovarian carcinoma in complete remission or with microscopic residual disease. Eur J Gynecol Oncol 12:457-461, 1991
15. Menczer J, Ben-Baruch G, Ritzel S: Intraperitoneal cisplatin chemotherapy in ovarian carcinoma patients who are clinically in complete remission. Gynecol Oncol 46:222-225, 1992
16. De Gramont A, Demuynck B, Louvet C: Survival with intraperitoneal cisplatin in advanced ovarian cancer after second-look laparotomy. Am J Clin Oncol 15:7-11, 1992
17. Tarraza HM Jr, Boyce CR, Smith G: Consolidation intraperitoneal chemotherapy in epithelial ovarian cancer patients following negative second-look laparotomy. Gynecol Oncol 50:287-290, 1993
18. Dufour P, Bergerat J-P, Barats J-C, Giron C, Duclos B, Dellenbach P, Ritter J, Renaud R, Audhuy B, Oberling F: Intraperitoneal mitoxantrone as consolidation treatment for patients with ovarian carcinoma in pathologic complete remission. Cancer 73:1865-1869, 1994
19. McGuire WP, Hoskins WJ, Brady MF, Kucera PR, Partridge EE, Look KY, Clarke-Pearson DL, Davidson M: Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med 334:1-6, 1996
20. Alberts DS, Liu PY, Hannigan EV, O'Toole R, Williams SD, Young JA, Franklin EW, Clarke-Pearson DL, Malviya VK, DuBeshter B, Adelson MD, Hoskins WJ: Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous Cyclophosphamide for stage III ovarian cancer. N Engl J Med 335:1-6, 1996